欧林生物: 成都欧林生物科技股份有限公司第七届董事会第四次会议决议公告

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. has made significant decisions during its board meeting, including the termination of a simplified procedure for issuing A-shares and the acquisition of a 15% stake in its subsidiary, which reflects the company's strategic focus on enhancing control and management efficiency [1][2][3] Group 1: Board Meeting Details - The seventh board meeting was held on August 29, 2025, with all nine directors present, and the meeting's procedures complied with relevant laws and regulations [1] - The board unanimously agreed to terminate the simplified procedure for issuing A-shares, indicating a careful decision-making process that will not adversely affect the company's operations or shareholder interests [1][2] Group 2: Acquisition of Subsidiary Stake - The company plans to exercise its right of first refusal to acquire 15% of the shares from minority shareholders of its subsidiary, Chengdu Xinno Ming Biotechnology Co., Ltd., with a purchase price not exceeding RMB 45 million [2][3] - This acquisition is aligned with the company's strategic development goals and aims to enhance control over the subsidiary, thereby improving overall management efficiency [2][3]